FORM PTO-1449 (Rev 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 36193	SERIAL NO. 10/536,584	1000		
	RMATION DISCLOSURE TEMENT BY APPLICANT	APPLICANT: Jallal Messadek				
(Use s	everal sheets if necessary)	FILING DATE: April 7, 2006	GROUP:1615	CONF. NO: 9204		

U.S. PATENT DOCUMENTS

	EXAM. INITIAL		DOCUMENT NUMBER							INVENTOR NAME	CLASS	SUB- CLASS	ISSUE DATE (PATENT); PUBLICATION DATE (PUBLISHED APPLICATION); OR FILING DATE (NON-PUBLISHED APPLICATION)
l			2006/0233877							Messadek et al.			October 19, 2006
l			5 7 1 6 9 4 1				4	1	Rabinoff			February 10, 1998	
			2002/0183380							Hunter			December 5, 2002

FOREIGN PATENT DOCUMENTS

1 01	CEIOIT ATEN	DOCUMENTS				
DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLA	TION
					YES	NO
FR 2,590M (927 734)	12 Mars 1963	France			X (see other docs)	
WO 02/062322	15 August 2002	WIPO			×	
WO 02/00213	3 January 2002	WIPO			×	
WO 2004/032916	22 April 2004	WIPO			×	
WO 97/38686	23 October 1997	WIPO			×	
FR 70.47549 (2.119.889)	31 Decembre 1970	France			X (google only)	

OTHER DOCUMENTS (Including Publisher, Author, Title, Relevant Pages, and Date and Place of Publication)

McGregor et al., "A Controlled Trial of the Effect of Folate Supplements on Homocysteine, Lipids and Hemorheology in End-State Renal Disease," Nephron, Vol. 85, No. 3, 2000, 215-220
Gurfinkel et al., "Fast platelet suppression by lysine acetylsalicylate in chronic stable coronary patients. Potential clinical impact over regular aspirin for coronary syndromes," <u>Clin. Cardiol.</u> , 2000 Sep.23(9):697-700.
Klasing et al., "Dietary Betsine Increases Intraepithelial Lymphocytes in the Duodenum of Coccidia-Infected Chicks and Increases Functional Properties of Phagocytes," 2002, <u>The American Society for Nutritional Sciences</u> . J. Nutr. 132; 2274-2282, 2002
Schmidt et al., "Total nitric oxide production is low in patients with chronic renal disease," Kidney International, 2000, 58, 1261-1266
Letter Regarding Dietary Supplement Health Claim for Folic Acid, Vitamin B6, and Vitamin B12 and Vascular Disease (Docket No. 99P-3029), to Jonathan W. Emord of Emord & Associates, PC, from Christine J. Lewis of the FDA, November 28, 2000
Malinow, "Plasma homocyst(e)ine and arterial occlusive diseases a mini-review," Clin. Chem., 1995 Jan,41(1):173-6
al Awami et al., "Homocysteine levels in patients with Raynaud's phenomenon," Vasa, 2002 May; 31(2): 87-90
Stammler et al., "The prevalence of hyperhomocysteinemia in thromboangitis obliterans. Does homocysteine play a role pathogenetically?" Dtsch Med Wochenschr , 1996 Nove 15;121(46):1417-23.
English Translation of French Patent 2,590M issued on June 15, 1964, 11 pages

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY, DOCKET NO. 36193	SERIAL NO. 10/536,584		
	DRMATION DISCLOSURE TEMENT BY APPLICANT	APPLICANT: Jallal Messadek			
(Use	several sheets if necessary)	FILING DATE: April 7, 2006	GROUP: 1615	CONF. NO: 9204	

U.S. PATENT DOCUMENTS

	C.C. FALLIT DOCUMENTO											
EXAM. INITIAL			DOG	CUMI	ENT	NUM	BER		INVENTOR NAME	CLASS	SUB- CLASS	ISSUE DATE (PATENT); PUBLICATION DATE (PUBLISHED APPLICATION); OR FILING DATE (NON-PUBLISHED APPLICATION)
	4 9 6 8 7 1 9				9	Brevetti			November 6, 1990			
		200	2002/0065320						Messadek			May 30,2002
		6	0	0	8	2	2	1	Smith et al.	Smith et al.		December 28, 1999
		6 6 2 4 1 8 0		South et al.			September 23, 2003					
		6 7 6 2 0 2 5			5	Cubicciotti			July 13, 2004			

FOREIGN PATENT DOCUMENTS

10	KLIGNTAILN	I DOCOMENTO				
DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
					YES	ΝО
WO 2004/049095	10 June 2004	WIPO			×	
WO 01/56609	9 August 2001	WIPO			X (ab- stract only)	
WO 02/47493	20 June 2002	WIPO			×	
WO 2005/065675	July 21, 2005	WIPO			×	
WO 2005/004854	20 January 2005	WIPO			X (ab- stract only)	

OTHER DOCUMENTS (Including Publisher, Author, Title, Relevant Pages, and Date and Place of Publication)

Relevant Pages, and Date and Place of Publication)
McCarty, "Co-administration of equimolar doses of betaine may alleviate the hepatotoxic risk associated with niacin therapy," Med-Hypothesis, 2000 Sep. 55(3): 189-94
Letter regarding Petition for Health Claim: Folic Acid, Vitamin B6, and Vitamin B12 Dietary Supplements and Vascular Disease [Docket No. 99P-3029], to Jonathan W. Emord of Emord & Associatess from Christine J. Lewis of the FDA, February 9, 2001
Birnie et al., "Antimicrobial Evaluation of N-Alkyl Betaines and N-Alkly-N,N-Dimethylamine Oxides with Variations in Chain Length," Antimicrobial Agents and Chemotherapy, Sept., 2000, p. 2514-2517
Palatka Karoly et at. "Changes in the expression and distribution of the inducible and endothelial nitric oxido synthase in mucosal biopsy specimens of inflammatory bowel disease," Scandinavian Journal of Gastroenerology, 2005. vol. 40, no. 6, pp. 670-680.
van Hoek, "Non-alcoholic fatty liver disease" a brief review, "Scandinavian Journal of Gastroenerology Supplement, 2004;(241):56-9.
Mendes et al., "Recent advances in the treatment of non-alcoholic fatty liver disease," Expert Opin. Investig. Drugs, 2005 Jan;14(1):29-35.

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of the form with next communication to applicant. ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.V./

	FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 36193	SERIAL NO. 10/536,584			
		RMATION DISCLOSURE TEMENT BY APPLICANT	APPLICANT: Jallal Messadek				
-	(Use s	everal sheets if necessary)	FILING DATE: April 7, 2006	GROUP: 1615	CONF. NO: 9204		

U.S. PATENT DOCUMENTS

		0.0. I ATENT DO	001111				
EXAM. INITIAL	DOCUMENT NUMBER	INVENTOR NAME	CLASS	SUB- CLASS	ISSUE DATE (PATENT); PUBLICATION DATE (PUBLISHED APPLICATION); OR FILING DATE (NON-PUBLISHED APPLICATION)		
	US 2006/0233877	Messadek et al.			October 19, 2006		
	US 2006/0034918	Messadek			February 16, 2006		
	US 2006/0128657	Messadek			June 15, 2006		

FOREIGN PATENT DOCUMENTS

 					0.	CLIOIT I ATEIT	DOCOMENTE				
DO	CUM	ENT I	MUM	3ER		PUBLICATION DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLA	ATION
										YES	NO
WO 2005/011645						10 February 2005	WIPO			×	
WO 2004/049095						10 June 2004	WIPO			×	
WO 2005/011642						10 February 2005	WIPO			×	
WO 2006/007671						26 January 2006	WIPO			X (google trans- lation)	

OTHER DOCUMENTS (Including Publisher, Author, Title, Relevant Pages, and Date and Place of Publication)

Korzh, "Relationship Between Endothelial Nitric Oxide Synthesis and Low-Grade Chronic Inflammation," European Atherosclerosis Society, 73rd EAS Congress, Salzburg, Austria, July 7-10, 2002
Didier et al., "Distal cutaneous necrosis, an unusual etiology: hyperhomocysteinemia," <u>Ann Dermatol Venereol</u> , 1999 Nov.126(11).822-5. PMID. 10612875
Gurfinkel et al., "East Platelet Suppression by Lycino Acetylsalicytate in Chronic Stable Coronary Patients. Potentia Clinical Impact Over Kegular Aspirin for Coronary Syndromes," Abstracts–Myocardiol Ischemia and Infarction, IACC, February 2000, 408A-4059.
Bonaa et al., "Homocysteine lowering and cardiovascular events after acute myocardial infarction," N. Eng. J. Med., 2006 April 13., 354(15):1578-88. Epub 2006 March 12.
Lonn et al. "Homocysteine lowering folic acid and B vitamins in vascular disease," N. Eng. J. Med., 2006 April 13;354(15):1667-77. Epub 2006 March 12.
Approval of Cilostazol, January 06, 2006, Center for Drug Evaluation and Research, www.fda.gov/cder/news/cilostazol/appproval.htm

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

/Jake Vu/ 02/24/2010

(Rev. 2-32) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE								ATTY, DOCKET NO. 36193				SERIAL NO. 10/536,584						
INFORMATION DISCLOSURE STATEMENT BY APPLICANT									APPLICANT: Jallal Messadek									
(Use several sheets if necessary)								FILING DATE: April 7, 2006			GF	GROUP: 1615			CONF. NO: 9204			
				-		ι	J.S. PATEN	T DC	СПМІ	ENT	s							
EXAM. INITIAL		DOCUMENT NUMBER					INVENTOR N	AME CLA		s	SUB- CLASS		ISSUE DATE (PATENT); PUBLICATION DATE (PUBLISHED APPLICATION); OR FILING DATE (NON-PUBLISHED APPLICATION)					
		US 2003/0203878					Flashner-Barak	et al.					October 30, 2003					
		6 8 8 1 4 2 0					Flashner-Barak et a						April 19, 2005					
					F	OF	REIGN PAT	ENT	DOCL	IME	NTS							
		DOCUMENT NUMBER					PUBLICATION DATE		COUNTRY				CLASS SUB- CLASS			TRANSLATION		
																YES	NO	
		WO 02	/066002				August 29, 2002	2	WIPO							х		
		WO 98	/56497			-	December 17, 1998		WIPO							×		
		WO 99	9/45913				September 16, 1999		WIPO							×		
<u></u>	WO 04/091601						October 28, 200	, 2004 WIPO						<u> </u>		×	<u> </u>	
	Ī		Rel	eva	nt i	Pag ndoz	ENTS (Includes, and Dames, and Dames, "A Primary Care 15, 2000, http://ww	te ar	nd Place	e o	of Pu	blic Clau	ation)	America	ın Fe	amily Physic	cian,	
			Ceaufou Médican	r and nent.	Beau P.V. r	four.	"Nouvelles 25500 27.734, No. 2.590	essociations antinévralgiques à tolérance améliorée." Brovet Spécial De 2.590, 1964, pp. 1-5										
	2/23/96 Chinese document (pp. 91-93) with English translation titled "Homocysteine and Vascular Dis												Disease," 5	pages				
		Da Silva and Sobol, Abstract from Entrez-PubMed web page entitled "Anicoagulants" to bleed or not to bleed, that is the question, "Semin Vasc. Surg. 2002 Dec;15(4):256-67, 1 page														l, that		
		JACC Abstracts, Myocardial Ischemia and Infarction, February 2000, 1196-107, pp. 408-409																
		Lasch H.G., Abstract from Entrez-PubMed web page entitled "Principles of Drug Prevention of Thrombosis Langenbecks Arch Chir., 1986;369:451-7, 1 page													ombosis,"			
	Marcel et al. Abstract from Entrez-PubMed web page entitled "From Virchow to red cells (the unended que: Clin Lab. 1983.13 Suppl 37-18.1 nage 1. Zoller et al., Betaine-Palmitate Reduces Acetylsalicyclic Acid-induced Gastric Damage in Rats, Scand J. Gastroenterol 2001 (3), pp. 811-816													ended quest	t).", Ric			
														Scand J.				
			Antithro	mboti	effe	ct of	Betaine, Bio Ethic	, Janua	ary 2003,	op. 1-	30							
			Copy of	Office	Acti	on in	09/945,391 dated	Nover	nber 5, 20	02, 5	pages							
	Copy of Office Action in 09/945,391 dated June 4, 2003, 14 pages																	
	1		Copy of	Office	Actio	on in	10/635,048 dated	Decer	nber 6, 20	05, 8	pages							
			Copy of	Office	Actio	on in	10/635,048 dated	Decer	mber 21, 2	006,	16 page	es						

Copy of Office Action in 10/635,048 dated September 20, 2007, 25 pages